ABTA PARTNERS WITH NATIONAL CANCER INSTITUTE TO ACCELERATE RARE BRAIN TUMOR RESEARCH
Brain and central nervous system (CNS) tumor diagnoses only represent 1.4 percent of all cancers, making it challenging for the research community to conduct clinical trials with a small patient population. The American Brain Tumor Association is partnering with the National Cancer Institute’s NCI-CONNECT initiative to advance the understanding of rare adult brain tumors and CNS cancers to improve approaches to care and treatment.
FIBER ARTIST RECONSTRUCTS THE BRAIN TO SUPPORT THE ABTA
Artist Laura Bundesen stitches together art and neuroscience to create a sense of joy, wonder and inspiration. Her colorfully embroidered “Word Cloud” adorned with words of inspiration is available for purchase with 20% of sales donated to the American Brain Tumor Association.
Check out Laura’s art, as well as other charitable shopping opportunities to shop for good!
SHARON MERCER: MEETING THE CHALLENGES OF BRAIN CANCER AS A DEVOTED CAREGIVER
Learn how Sharon Mercer got through the ups and downs of her husband’s brain tumor diagnosis as his caregiver.
UP NEXT IN THE JUNE EDITION OF MINDMATTERS
The American Brain Tumor Association heads to the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 – June 4, 2019 in Chicago, IL. The ABTA, including President and Chief Executive Officer Ralph A. DeVitto, Chief Mission Officer Nicole Wilmarth, PhD and Director of Research and Grants, Heather Calderone, PhD, will report on key medical, treatment and care takeaways in the June edition of MindMatters.
The ASCO Annual Meeting is the largest conference that brings together the best and brightest in cancer research and clinical practice from around the world. The conference forges opportunities to learn, collaborate and network across a range of disciplines and professions in the pursuit to uncover innovative and effective medical therapies for cancer, including brain cancer.
Concurrently, on June 2, the ABTA will present preliminary research findings from the first phase of the ABTA’s Metastatic Brain Tumor Initiative at the ASCO Annual Meeting. The ABTA’s research study was approved for poster presentation out of more than 6,200 abstract submissions. It was also one of the few selected on this topic, within the brain tumor and central nervous system category. This demonstrates the importance of these findings in such a competitive landscape at the premiere oncology meeting.
Stay tuned for the June edition of MindMatters!
Upcoming Events
 |
 |
 |
| June 1, 2019 BT5K Run & Walk Columbus Columbus, OH |
June 1, 2019 Paul Fabbri Memorial Golf Classic Buffalo Grove, IL |
June 9, 2019 4th Annual Makers Market & Cut-A-Thon Guilford, CT |
| LEARN MORE | LEARN MORE | LEARN MORE |
About Meet Hope Head On
Because of the generous support from people like you, the ABTA has given over $35 million for brain tumor research. The ABTA’s campaign, “Meet Hope Head On,” created for our 50th anniversary, is focused on raising $50 million, in part to fund critical brain tumor research. This campaign is vital for continuing the kind of work that led to the recent FDA approval of vorasidenib, a breakthrough treatment for low-grade glioma.
